EA202190151A1 - Фармацевтическая комбинация для применения при возрастных и/или дегенеративных заболеваниях - Google Patents
Фармацевтическая комбинация для применения при возрастных и/или дегенеративных заболеванияхInfo
- Publication number
- EA202190151A1 EA202190151A1 EA202190151A EA202190151A EA202190151A1 EA 202190151 A1 EA202190151 A1 EA 202190151A1 EA 202190151 A EA202190151 A EA 202190151A EA 202190151 A EA202190151 A EA 202190151A EA 202190151 A1 EA202190151 A1 EA 202190151A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pharmaceutical combination
- degenerative diseases
- aged
- diseases
- stabilization
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000003412 degenerative effect Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 230000006641 stabilisation Effects 0.000 abstract 2
- 238000011105 stabilization Methods 0.000 abstract 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 abstract 1
- 229940123208 Biguanide Drugs 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Настоящее изобретение относится к фармацевтической комбинации для применения в лечении, предупреждении и/или стабилизации возрастных заболеваний и/или дегенеративных заболеваний. В частности, указанная фармацевтическая комбинация содержит бигуанид и ингибитор ацетилхолинэстеразы и/или их N-оксид, гидрат, фармацевтически приемлемую соль или сольват. Настоящее изобретение дополнительно также направлено на применение указанной фармацевтической комбинации для предупреждения, стабилизации и/или уменьшения количества жалоб, связанных с возрастными заболеваниями, и/или жалоб, связанных с дегенеративными заболеваниями; и для улучшения показателя продолжительности жизни и/или продолжительности жизни с сохранением здоровья.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18180906 | 2018-06-29 | ||
| PCT/EP2019/067645 WO2020002715A1 (en) | 2018-06-29 | 2019-07-01 | Pharmaceutical combination for use in age-related and/or degenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190151A1 true EA202190151A1 (ru) | 2021-04-16 |
Family
ID=62837788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190151A EA202190151A1 (ru) | 2018-06-29 | 2019-07-01 | Фармацевтическая комбинация для применения при возрастных и/или дегенеративных заболеваниях |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12090124B2 (ru) |
| EP (2) | EP3813882B1 (ru) |
| JP (2) | JP2021530459A (ru) |
| KR (2) | KR102576433B1 (ru) |
| CN (1) | CN112654367B (ru) |
| AU (2) | AU2019294573B2 (ru) |
| BR (1) | BR112020026456A2 (ru) |
| CA (1) | CA3104397C (ru) |
| EA (1) | EA202190151A1 (ru) |
| ES (1) | ES2965834T3 (ru) |
| IL (2) | IL279732B2 (ru) |
| MA (1) | MA53007A (ru) |
| PL (1) | PL3813882T3 (ru) |
| SG (1) | SG11202012731WA (ru) |
| WO (1) | WO2020002715A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240049717A (ko) | 2022-10-07 | 2024-04-17 | 순천향대학교 산학협력단 | 플로리진의 노화 관련 질환의 예방 또는 치료 용도 |
| WO2024099971A1 (en) | 2022-11-07 | 2024-05-16 | Rejuvenate Biomed Nv | Metformin minitablets |
| WO2024099974A1 (en) | 2022-11-07 | 2024-05-16 | Rejuvenate Biomed Nv | Galantamine minitablets |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| WO2000041540A2 (en) * | 1999-01-11 | 2000-07-20 | Atanas Russinov Djananov | Herbal supplement for increased muscle strength and endurance for athletes |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| WO2009039313A1 (en) * | 2007-09-18 | 2009-03-26 | Stephen Wills | Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors |
| WO2012012156A1 (en) * | 2010-07-21 | 2012-01-26 | Myomics, Inc. | Methods and compositions for the improvement of skeletal muscle function in a mammal |
| CN103860532B (zh) | 2014-03-11 | 2016-02-17 | 贡岳松 | 美金刚和二甲双胍的复方药用组合物及其制备方法 |
| CN104623671B (zh) | 2015-02-09 | 2017-11-17 | 徐云根 | 含有乙酰胆碱酯酶抑制剂和二甲双胍的复方药用组合物 |
-
2019
- 2019-07-01 ES ES19734401T patent/ES2965834T3/es active Active
- 2019-07-01 IL IL279732A patent/IL279732B2/en unknown
- 2019-07-01 AU AU2019294573A patent/AU2019294573B2/en active Active
- 2019-07-01 MA MA053007A patent/MA53007A/fr unknown
- 2019-07-01 CN CN201980043961.1A patent/CN112654367B/zh active Active
- 2019-07-01 US US17/255,662 patent/US12090124B2/en active Active
- 2019-07-01 BR BR112020026456-3A patent/BR112020026456A2/pt unknown
- 2019-07-01 JP JP2020572917A patent/JP2021530459A/ja active Pending
- 2019-07-01 EA EA202190151A patent/EA202190151A1/ru unknown
- 2019-07-01 KR KR1020217002941A patent/KR102576433B1/ko active IP Right Grant
- 2019-07-01 EP EP19734401.3A patent/EP3813882B1/en active Active
- 2019-07-01 EP EP23181463.3A patent/EP4257189A3/en active Pending
- 2019-07-01 PL PL19734401.3T patent/PL3813882T3/pl unknown
- 2019-07-01 IL IL309939A patent/IL309939A/en unknown
- 2019-07-01 WO PCT/EP2019/067645 patent/WO2020002715A1/en active Application Filing
- 2019-07-01 CA CA3104397A patent/CA3104397C/en active Active
- 2019-07-01 SG SG11202012731WA patent/SG11202012731WA/en unknown
- 2019-07-01 KR KR1020237030214A patent/KR20230145380A/ko not_active Application Discontinuation
-
2022
- 2022-06-15 AU AU2022204173A patent/AU2022204173A1/en not_active Abandoned
-
2023
- 2023-02-03 JP JP2023015268A patent/JP7542662B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12090124B2 (en) | 2024-09-17 |
| BR112020026456A2 (pt) | 2021-03-23 |
| EP4257189A3 (en) | 2023-12-20 |
| IL279732A (en) | 2021-03-01 |
| EP4257189A2 (en) | 2023-10-11 |
| EP3813882C0 (en) | 2023-08-09 |
| IL279732B1 (en) | 2024-02-01 |
| SG11202012731WA (en) | 2021-01-28 |
| PL3813882T4 (pl) | 2024-04-08 |
| KR20230145380A (ko) | 2023-10-17 |
| US20210267918A1 (en) | 2021-09-02 |
| CA3104397A1 (en) | 2020-01-02 |
| JP7542662B2 (ja) | 2024-08-30 |
| ES2965834T3 (es) | 2024-04-17 |
| JP2021530459A (ja) | 2021-11-11 |
| CN112654367B (zh) | 2023-08-04 |
| KR20210042312A (ko) | 2021-04-19 |
| IL309939A (en) | 2024-03-01 |
| NZ772236A (en) | 2024-02-23 |
| AU2019294573A1 (en) | 2021-02-18 |
| CA3104397C (en) | 2023-08-01 |
| PL3813882T3 (pl) | 2024-04-08 |
| AU2022204173A1 (en) | 2022-07-07 |
| MA53007A (fr) | 2021-05-05 |
| AU2019294573B2 (en) | 2022-03-31 |
| EP3813882B1 (en) | 2023-08-09 |
| IL279732B2 (en) | 2024-06-01 |
| WO2020002715A1 (en) | 2020-01-02 |
| CN112654367A (zh) | 2021-04-13 |
| KR102576433B1 (ko) | 2023-09-12 |
| JP2023055890A (ja) | 2023-04-18 |
| EP3813882A1 (en) | 2021-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
| MX2021008342A (es) | Derivados de pirazol como inhibidores de calicreina plasmatica. | |
| EA201890318A1 (ru) | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ | |
| WO2018134685A3 (en) | Compounds | |
| EA201791576A1 (ru) | Ингибитор jak | |
| EA202090052A1 (ru) | Содержащие имидазол ингибиторы alk2 киназы | |
| EA201592199A1 (ru) | Производные бипиразола в качестве ингибиторов jak | |
| PH12016502355A1 (en) | Pharmaceutical composition | |
| EA202190681A1 (ru) | Амиды диметиламиноазетидина в качестве jak ингибиторов | |
| EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
| SA520412335B1 (ar) | مشتقات أوكسي فلورو ببريدين كمثبط كيناز | |
| EA202191239A1 (ru) | Соединения и их применение для лечения дефицита 1-антитрипсина | |
| EA202190151A1 (ru) | Фармацевтическая комбинация для применения при возрастных и/или дегенеративных заболеваниях | |
| MX362806B (es) | Inhibidores biciclicos. | |
| EA202190686A1 (ru) | 5-7-членные гетероциклические амиды в качестве ингибиторов jak | |
| EA201991253A1 (ru) | Бензодиазолиевые соединения в качестве ингибиторов enac | |
| EA201692470A1 (ru) | Фармацевтические комбинации | |
| TW201613577A (en) | Pharmaceutical combinations | |
| MX2018008307A (es) | Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk). | |
| EA201890862A1 (ru) | Ингибиторы плазменного калликреина человека | |
| EA202190153A1 (ru) | Составы ингибитора axl/mer | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| EA201800565A1 (ru) | Композиция для лечения заболеваний уха, содержащая (+)-азасетрон |